A study published by chemists working for the biopharmaceutical company Cephalon to develop a successor to the wakefulness-promoting agent (or eugeroic) modafinil reported that fluorenol was 39% more effective than modafinil at keeping mice awake over a 4-hour period. It is a weak dopamine reuptake inhibitor with an IC50 of 9 μM, notably 59% weaker than modafinil (IC50 = 3.70 μM) despite being a stronger wakefulness-promoting agent, potentially making it even less liable for addiction. It also showed no affinity for cytochrome P450 2C19, unlike modafinil. No human trials have yet been published as of 2015.
Dit interpreteer ik als nog meer wakefulness, nog minder upper gevoel (strak staan) en potentieel minder risico's met de lever. Klinkt interessant niet?
Heeft iemand dit al geprobeerd?